Tag «Chronic Lymphocytic Leukemia»

CC-90009

It’s only fair to share… CC-90009 CC-90009-AML-001 CAS 1860875-51-9 461.8 g/mol, C22H18ClF2N3O4 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide 4-Chloro-N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-α,α-difluorobenzeneacetamide Benzeneacetamide, 4-chloro-N-[[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1-oxo-1H-isoindol-5-yl]methyl]-α,α-difluoro- Phase 1 Clinical, Acute myelogenous leukemia, Protein cereblon modulator Useful for treating chronic lymphocytic leukemia, chronic myelocytic leukemia, acute lymphoblastic leukemia or acute myeloid leukemia. Celgene is developing CC-90009, a cereblon E3 ligase modulator, for treating AML; in January 2019, data from a …

GDC 0853, Fenebrutinib

It’s only fair to share…   . Picture credit….Bethany Halford GDC 0853, Fenebrutinib GDC-0853; RG 7845 Molecular Formula: C37H44N8O4 Molecular Weight: 664.79646 g/mol 2-[3-(hydroxymethyl)-4-[1-methyl-5-[(7-methyl-6,8-dihydro-5H-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)amino]-6-oxo-3-pyridyl]-2-pyridyl]-3,4,6,7,8,9-hexahydropyrazino[1,2-a]indol-1-one 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 3-[3-(hydroxymethyl)-4-[5-[[5-[(2S)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]-2-pyridyl]amino]-6-oxo-1H-pyridin-3-yl]-2-pyridyl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one 2H-Cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one, 2-[1,6-dihydro-3′-(hydroxymethyl)-1-methyl-5-[[5-[(2S) -2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino] -6-oxo[3,4′-bipyridin]-2′-yl]-3,4,7,8-tetrahydro-7,7- dimethyl- s ISoMER 1434048-34-6 desired r iSoMER 1434048-57-3 undesired   Phase 1 Patients with Patients with Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.. @genentech‘s Btk inhibitor https://clinicaltrials.gov/ct2/show/NCT01991184 Bruton tyrosine …